small molecule

NORLIQVA

AMLODIPINE BESYLATE

Loss of exclusivityFebruary 2041latest FDA-listed patent expiry
CompanyCMP DEVELOPMENT LLC

Drug detail

Brand nameNORLIQVA
Active ingredientAMLODIPINE BESYLATE
StrengthEQ 1MG BASE/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2022
Marketing statusRX

Listed patents

PatentExpiresType
12226528February 2041product
11458095February 2041product
12005141February 2041product
12440441February 2041product
11723866February 2041product
11253474February 2041product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

NORLIQVA patent cliff — loss of exclusivity February 2041 | CliffBio